AI-powered search
AI-powered search

Live Evaluations

What is New in Non-Steroidal Topical Options for Atopic Dermatitis and Psoriasis: Clinical Insights for Dermatology PAs and NPs : FCPANP23 Seminar-in-Depth

About

Phase 3 ADORING2 study with tapinarof in children with atopic dermatitis ages 2 and above show approximately a 50% improvement in? Start the activity to find out the answer!

a. V-IGA-AD but not EASI75 and PP-NRS
b. V-IGA-AD and EASI75 but not PP-NRS
c. V-IGA-AD and EASI75 and PP-NRS
d. EASI75 and PP-NRS but not V-IGA-AD

This activity is supported by an educational grant from Arcutis, Dermavant, and Incyte.

Learning Objectives

At the completion of this activity, participants should be better able to:

  • Identify challenges associated with the use of topical corticosteroids in patients with AD and psoriasis

  • Review nonsteroid topical agents for the treatment of AD and psoriasis

  • Discuss clinical considerations for PAs and NPs who prescribe topical therapies to patients with AD and psoriasis

Intended Audience
This activity has been designed for dermatologists, dermatology physician assistants, dermatology nurse practitioners, and other providers involved in the care of patients.
Faculty
James
James Del Rosso, DO

Adjunct Clinical Professor, Dermatology
Touro University Nevada
Henderson, NV

Linda
Linda Stein Gold, MD

Director Clinical Research 
Henry Ford Health System 
Detroit, MI

Accreditation Statement

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of University of Nevada, Reno School of Medicine and CMEsquared. The University of Nevada, Reno School of Medicine is accredited by the ACCME to provide continuing medical education for physicians.

Credit Designation Statement

The University of Nevada, Reno School of Medicine designates this enduring activity for a maximum of 0.50 AMA PRA Category 1 CreditsTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Disclosures & Disclaimers

Disclosures are as follows:

James Q. Del Rosso, DO

Grant/Research Support: Aclaris, Amgen, Anaptys Bio, Arcutis, Athenex, Bausch (Ortho), Biorasi, Botanix, Brickell, Cara Therapeutics, Cassiopea, Dermavant, EPI Health, Galderma, Genentech, Incyte, Janssen, LEO, Lilly, Novan, Pfizer, Ralexar, Sanofi Genzyme Regeneron, Sol-Gel, SUN, Vyne

Consultant: Abbvie, Aclaris, Almirall, Amgen, Arcuits, Bausch (Ortho), Biofrontera, Biopharmx, Blue Creek, BMS, Cassiopea, Dermata, Dermavant, Encore, EPI Health, Evoummune, Ferndale, Galderma, Incyte, Jem Health, LEO, La Roche Posay, Lilly, MC2, Novan, Pfizer, Sanofi Genzyme Regeneron, Sente, Sol-Gel, Sonoma, SUN, UCB, Verrica, Vyne

Speakers’ Bureau or Honoraria: Abbvie, Aclaris, Almiral, Amgen, Bausch (Ortho), Biofrontera, Encore, EPI Health Ferndale, Galderma, Genentech, Jem Health, LEO, Lilly, Pfizer, Sanofi Genzyme Regeneron, SUN, UCB, Verrica, Vyne

Linda F. Stein Gold, MD

Grant/Research Support: Arcutis, BMS, Incyte, Dermavant, Galderma, Lilly, AbbVie

Consultant: Arcutis, BMS, Incyte, Dermavant, Galderma, Lilly, AbbVie

Speakers’ Bureau or Honoraria: Leo, AbbVie, Almirall, Galderma, Pfizer, Sanofi, Regeneron

The University of Nevada, Reno School of Medicine discloses that all relevant conflicts have been satisfactorily mitigated.


Dermsquared

The leading solutions platform for dermatology professionals to elevate patient care.

Contact Us

Support

Subscribe now

Enter your email to get the latest updates.

© 2024 dermsquared | All Rights Reserved